Citation Impact
Citing Papers
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Gastric cancer
2016 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
1998
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
2012 Standout
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
1998
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
2008 Standout
Enzyme-Catalyzed Activation of Anticancer Prodrugs
2004
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
2001 Standout
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer
1997
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
1997
Cancer drug resistance: an evolving paradigm
2013 Standout
Metabolism and action of amino acid analog anti-cancer agents
1990
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides
2007 StandoutNobel
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
1997 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Metabolism and mechanism of action of 5-fluorouracil
1990
Colorectal cancer prevention and treatment
2000
Safety and antitumor activity of recombinant soluble Apo2 ligand
1999 Standout
P53 overexpression predicts poor chemosensitivity to high‐dose 5‐fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
2001
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Toxicity profile of dexrazoxane (zinecardR, icrf-187, adr-529, nsc-169780), a modulator of doxorubicin cardiotoxicity
1991
Adjuvant therapy for colon cancer
1997
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes
2011
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
1997
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
1996
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Apoptosis
2002 Standout
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma
1994
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Targeting gene expression to hypoxic tumor cells
1997 StandoutNobel
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Determination of microsatellite instability,p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival
2001
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer
1997
Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil
1995
Clinical Pharmacokinetics of Interferons
1990
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
2002 Standout
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma
1993
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
1989
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
1998
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
Evaluating the role of photodynamic therapy in the management of pancreatic cancer
1995
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Clinical imaging of cancer metastasis
2000
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
1996
Enhancement of 5-fluorouracil's anticancer activity by dipyridamole
1989
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
1999
Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling
2016
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
2004
Doxorubicin (adriamycin) cardiomyopathy.
1983
Anticancer Activity Expressed by a Library of 2,9-Diazaperopyrenium Dications
2015 StandoutNobel
Anthracycline Cardiotoxicity: From Bench to Bedside
2008
5-Fluorouracil Incorporated into DNA Is Excised by the Smug1 DNA Glycosylase to Reduce Drug Cytotoxicity
2007 StandoutNobel
Polymeric Systems for Controlled Drug Release
1999 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
2002 Standout
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
2004
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer
1992
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Structural and Biochemical Studies of a Fluoroacetyl-CoA-Specific Thioesterase Reveal a Molecular Basis for Fluorine Selectivity
2010 StandoutNobel
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Chemistry of Biologically Important Synthetic Organoselenium Compounds
2001 Standout
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer
1999
5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity.
1981
Emerging Targets in Photopharmacology
2016 StandoutNobel
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis
1982
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer
1999
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Role of uridine phosphorylase in the anabolism of 5-fluorouracil
1985
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
2004
Poly (ortho ester) matrices for controlled release of the antitumour agent 5-fluorouracil
1994
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Works of Bach Ardalan being referenced
Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.
1988
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
1988
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study
1991
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
1995
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies
1991
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.
1991
In the War Against Solid Tumors Arsenic Trioxide Need Partners
2014
Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled fab′ fragments of the immu-4 anti-carcinoembryonic antigen monoclonal antibody
1994
Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
1985
Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses
2005
Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.
1985
Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
1979
Continuous five‐day infusion of pala and 5FU: A pilot phase II trial
1983
Phase I study of continuous-infusion PALA and 5-FU.
1984
Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.
1999
Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
1981
Phase I study of recombinant beta ser 17 interferon in the treatment of cancer.
1986
Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo
1982
Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas
1982
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-l-aspartate on cell growth and ribonucleic acid synthesis in a human mammary carcinoma
1981
Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil.
1980
Long-term association of N-(phosphonacetyl)-L-aspartate with bone.
1981
Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response
1978
Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
1981
An update on the biochemistry of 5-fluorouracil
1981